Nicolas Calle-Martinez

Nottingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Trends and socio-economic disparities in chronic lymphocytic leukaemia 2014-2022: An England-wide cohort study from the UNCOVER group.

Trends and socio-economic disparities in chronic lymphocytic leukaemia 2014-2022: An England-wide cohort study from the UNCOVER group.

Journal: British journal of haematology

Published: April 02, 2026

Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.

Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma.

Journal: Leukemia & lymphoma

Published: February 25, 2026

Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.

Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study.

Journal: Blood advances

Published: February 04, 2026

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Journal: Blood advances

Published: February 04, 2026

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Journal: Blood advances

Published: January 21, 2026

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Journal: Blood advances

Published: January 21, 2026

MRI Predictors of Outcome in Primary Central Nervous System Lymphoma Patients Before and After Autologous Stem Cell Transplant.

MRI Predictors of Outcome in Primary Central Nervous System Lymphoma Patients Before and After Autologous Stem Cell Transplant.

Journal: EJHaem

Published: September 24, 2025

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Journal: HemaSphere

Published: September 05, 2025

Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Journal: Oncology and therapy

Published: July 29, 2025

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia.

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia.

Journal: British journal of haematology

Published: May 05, 2025

A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.

A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.

Journal: The Lancet. Haematology

Published: October 15, 2024

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.

Journal: American journal of hematology

Published: September 10, 2024

Showing 1-12 of 59

Last Updated: 09/26/2026